Merck-Gilead’s Combined HIV Treatment Sunlenca Shows Positive Results in...
A mid-phase trial featuring Gilead Sciences and Merck & Co.’s once-weekly HIV combination therapy has successfully met its primary 24-week endpoint and surpassed expectations by suppressing the...
View ArticleArcus’ HIF-2a Inhibitor Shows Positive Response Rate in Study
The latest research on Arcus Biosciences’ experimental HIF-2a inhibitor suggests that the firm may provide significant competition to Merck’s Welireg in treating kidney cancer. In the phase 1/1b ARC-20...
View ArticleMarinus to cut workforce and explore options after Ztalmy trial setback
Marinus Pharmaceuticals, a pharmaceutical company, has been dealt a blow after its Seizure drug, Ztalmy, did not reach the primary endpoint in the phase three trial for its treatment of seizures that...
View ArticleGSK Responds to Pfizer’s RSV Approval with Data Aiming for Similar Approval...
Two early-phase study trials suggest that GSK’s RSV vaccine, Arexvy, may benefit certain high-risk subgroups of younger adults and could potentially serve a broader population. This news comes shortly...
View ArticleAfter Roche and Takeda, Novartis steps into the molecular glue space
Roche first entered into an agreement with Orionis Biosciences in 2023 and paid the company up to $2 billion to access its investigational glues targeting challenging goals in neurodegeneration and...
View ArticleAbbVie Completes $1.4B Purchase of Aliada
AbbVie has agreed to spend $1.4 billion to purchase Aliada Therapeutics. Through this acquisition, AbbVie will be able to build upon the first class of anti-amyloid-beta antibodies by gaining ownership...
View ArticleAstellas and Europe Clash Over Approval of Geographic Atrophy Drug Izervay
Izervay by Astellas and Syfovre by Apellis are the major rivals in the United States Geographic Atrophy (GA) market, but both are struggling to enter the European market. Due to EMA’s CHMP second...
View ArticleApellis and Novartis both target rare kidney diseases with new drugs
Apellis Pharmaceuticals and Novartis recently shared data for their rare kidney disease drugs, pegcetacoplan and iptacopan. Both have performed well in treating C3 glomerulopathy (C3G) and improving...
View ArticleNovo scores license to use Ascendis’ TransCon platform for $285 million
In exchange for $285 million, Copenhagen-based Ascendis has agreed to help Novo Nordisk develop a once-a-month GLP-1 receptor antagonist and has granted a license to its TransCon platform to the big...
View ArticleAstraZeneca’s Obesity Pill Shows Positive Results in Early Trial
AstraZeneca announced that its new weight-loss medication, which was licensed from Eccogene of China, underwent early-stage testing and was found to be safe and acceptable. The news comes after the...
View ArticleImproving life science R&D outcomes with AI
Maximizing the potential AI/data-driven model of drug discovery requires the technology’s full integration into R&D. Biorelate’s Dr Ben Sidders explains. Pharma R&D latest disruption is via a...
View ArticleFDA to lift hold over Novavax flu-shot program
Maryland-based biotech Novavax experienced a clinical hold on its late-stage trial of COVID-influenza and standalone flu vaccines after a severe adverse effect, in the form of motor neuropathy...
View ArticleJ&J MedTech Gets FDA Nod for Varipulse PFA System
After the FDA approves Johnson & Johnson MedTech’s Varipulse technology for the management of atrial fibrillation, the company will join the U.S. pulsed field ablation market. As a result of the...
View ArticleBad News for AbbVie as Emraclidine Fails to Perform in Trials
AbbVie saw its valuation drop by around $40 billion following disappointing results from two clinical studies for emraclidine, an investigational drug intended to treat schizophrenia. The company had...
View ArticleRoche Partners with Transcription Factor Pioneer Flare in over $1.8B Cancer Deal
Roche has entered a groundbreaking deal worth more than $1.8B with Flare Therapeutics to advance new options for cancer therapy using transcription factors that are conventionally called undruggable....
View ArticleIncyte’s $750M Acquisition Shaken by Key Trial Pause and Asset Cuts
Incyte faced severe difficulties just a few months after purchasing Escient Pharmaceuticals for $750M. The biotech company has put on hold a key clinical trial due to preclinical toxicology issues and...
View Article71% of Patients in Cybin’s Small Depression Study Are in Remission
The Canada-based biotechnology company Cybin has announced the results of a Phase II study of the psilocin treatment CYB003 for major depressive disorder, claiming a 71% remission rate for patients who...
View ArticleJazz’s HER2 Bispecific Gets FDA Green Light
A bispecific antibody has emerged in the HER2 arena, exhibiting a different profile compared to conventional treatments and presenting a potential threat to AstraZeneca and Daiichi Sankyo’s leading...
View ArticleJ&J and Protagonist Therapeutics’ Oral Psoriasis Drug Shows Positive Results...
Hailed as the first oral peptide designed to selectively block IL-23, Johnson & Johnson and Protagonist Therapeutics’ icotrokinra, or JNJ-2113, originated from a 2017 collaboration between the two...
View ArticleResearch finds Merck’s treatment of lung disease can lower chance of death
Merck has released that its drug, Winrevair, reduced the risk of death in patients suffering from a rare condition that causes high blood pressure in the lungs or Pulmonary arterial hypertension (PAH),...
View Article